Crestor Helps Shelter AstraZeneca From Economic Storm
This article was originally published in The Pink Sheet Daily
Unlike other Big Pharmas, firm also gets a temporary reprieve from generic erosion of two brands.
You may also be interested in...
AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.
Despite the lack of innovative drugs highlighted in ASCO's media briefing on its upcoming annual meeting, there is a range of oncology development updates that will be presented - including some surprises
Bristol and FDA are working on cardiovascular outcomes study proposal. New deadline is July 30.